viewAdmedus Ltd

Admedus receives price and volume query after shares surge

Shares have increased by around 50% this week after hitting 10.5 cents yesterday.

Admedus Ltd - Admedus receives price and volume query after shares surge
These types of queries from the ASX are not uncommon

Admedus Ltd (ASX:AHZ) received a price and volume query from the ASX yesterday after its shares ran from 7.1 cents to hit a high of 10.5 cents on strong trading volume.

The company confirmed to the ASX that it was not aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities.

Admedus also took the opportunity to confirm that it was complying with the ASX Listing Rules and its obligations to disclose appropriate information to the market.

Completing $36.2 million transaction

In mid-October 2019, Admedus signed a $36.2 million deal to sell its VascuCel® and CardioCel® product range to LeMaitre Vascular Inc. (NASDAQ:LMAT).

Admedus is focused on delivering this transaction during the current quarter.

This is a transformational deal for Admedus and shifts its primary focus to advancing the Transcatheter Aortic Valve Replacement (TAVR) program and other potential products based on its proprietary ADAPT® platform technology.

The TAVR market is s anticipated to grow to $US12 billion within 5 to 6 years.

Proactive caught up with Admedus in London earlier this week.

Quick facts: Admedus Ltd

Price: 0.077 AUD

Market: ASX
Market Cap: $45.49 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Admedus Ltd named herein, including the promotion by the Company of Admedus Ltd in any Content on the Site, the Company receives from said...



Admedus Ltd proud to unveil its valves publicly for the first time in London

Admedus Ltd's (ASX:AHZ) CEO Wayne Paterson caught up with Proactive's Andrew Scott while in London. The firm recently made what's been described as a transformational move to sell off its CardioCel® and VascuCel® patch business. Paterson says the focus is now firmly on the Adapt...

on 20/11/19

2 min read